AVITA MEDICAL WKN: A0Q40S ISIN: AU000000AVH4 Kürzel: AVMXF Forum: Aktien Thema: Hauptdiskussion

AVITA Medical Announces FDA Approval of RECELL for Treatment of Full-Thickness Skin Defects https://www.businessupturn.com/brand-post/avita-medical-announces-fda-approval-of-recell-for-treatment-of-full-thickness-skin-defects/

AVITA Medical Reports First Quarter Financial Results and Affirms Full Year Guidance https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-reports-first-quarter-financial-results-and

Wann rechnet ihr mit den Zulassungen die im dritten Quartal 23 eingeführt werden sollen?

AVITA Medical Announces Update to Automation Device https://www.globenewswire.com/news-release/2023/04/13/2646762/0/en/AVITA-Medical-Announces-Update-to-Automation-Device.html

Kurseinbruch auf SVB Pleite zurückzuführen oder gab es andere news?

https://hotcopper.com.au/threads/ann-s-p-dji-announces-march-2023-quarterly-rebalance.7266043/

https://www.globenewswire.com/news-release/2023/02/27/2616077/0/en/AVITA-Medical-to-Host-Investor-Webinar-Briefing.html

https://finance.yahoo.com/news/brokers-upgrading-views-avita-medical-002043398.html

👍

🍀

AVITA Medical GAAP EPS of -$0.21 beats by $0.07, revenue of $9.46M beats by $0.63M https://seekingalpha.com/news/3940180-avita-medical-gaap-eps-of-0_21-beats-0_07-revenue-of-9_46m-beats-0_63m • AVITA Medical press release (NASDAQ:RCEL): Q4 GAAP EPS of -$0.21 beats by $0.07. • Revenue of $9.46M (+36.3% Y/Y) beats by $0.63M. • Our commercial revenue, which excludes BARDA revenue, increased by 37% to $9.4 million in the three months ended December 31, 2022, compared to $6.8 million in the same period in 2021.

AVITA Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance https://ir.avitamedical.com/news-releases/news-release-details/avita-medical-reports-fourth-quarter-and-full-year-2022

AVITA Medical Announces Management Changes and Fourth Quarter 2022 Earnings Conference Call https://www.globenewswire.com/news-release/2023/01/19/2592133/0/en/AVITA-Medical-Announces-Management-Changes-and-Fourth-Quarter-2022-Earnings-Conference-Call.html

https://m.marketscreener.com/quote/stock/AVITA-MEDICAL-INC-8777378/news/Avita-Medical-Files-Vitiligo-Indication-for-Skin-Restoration-Therapy-with-US-FDA-Shares-Fall-5-42574666/

AVH Avita Medical Inc Says Submits FDA PMA Application To Expand Indication To Vitiligo https://hotcopper.com.au/threads/news-avh-avita-medical-inc-says-submits-fda-pma-application-to-expand-indication-to-vitiligo.7152291/ AVITA Medical Inc RCEL.O : • SUBMITS FDA PMA APPLICATION TO EXPAND INDICATION TO VITILIGO • ANTICIPATE FULL LAUNCH OF THIS TREATMENT OPTION IN JANUARY 2025 • APPLICATION, IF APPROVED, WILL EXPAND THE INDICATION OF RECELL TO INCLUDE THE TREATMENT OF STABLE VITILIGO

●●●Nach der Zulassung erweitert diese Indikation unsere derzeitigen Marktchancen um mindestens das Dreifache und wird voraussichtlich ab Juli 2023 eine bedeutende Wachstumschance für uns darstellen.●●● Das wäre schon ein guter Anfang 👌